Temperature-dependent transport measurements with Arduino

The current performances of single-board microcontrollers render them attractive, not only for basic applications, but also for more elaborate projects, amongst which are physics teaching or research. In this article, we show how temperature-dependent transport measurements can be performed by using an Arduino board, from cryogenic temperatures up to room temperature or above. We focus on two of the main issues for this type of experiments: the determination of the sample temperature and the measurement of its resistance. We also detail two student-led experiments: evidencing the magnetocaloric effect in Gadolinium and measuring the resistive transition of a high critical temperature superconductor. Received: 7 July 2018,  Accepted: 27 September 2018; Edited by: A. Marti,  M. Monteiro;  Reviewed by: R. Marotti, Instituto de Física, Facultad de Ingeniería - Universidad de la República, Uruguay; DOI: http://dx.doi.org/10.4279/PIP.100007 Cite as: A Hilberer, G Laurent, A Lorin, A Partier, J Bobroff, F Bouquet, C Even, J M Fischbach, C A Marrache Kikuchi, M Monteverde, B Pilette, Q Quay,  Papers in Physics 10, 100007(2018) This paper, by A Hilberer, G Laurent, A Lorin, A Partier, J Bobroff, F Bouquet, C Even, J M Fischbach, C A Marrache Kikuchi, M Monteverde, B Pilette, Q Quay, is licensed under the Creative Commons Attribution License 4.0.    

Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma

Background

Pembrolizumab and nivolumab are immune checkpoint inhibitors targeting PD-1 that have recently been approved in pretreated recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC) patients. In the clinic, some patients seem not only not to benefit from anti-PD-L1/PD-1 agents but rather to experience an acceleration of tumor growth kinetics (TGK).

Patients and methods

We retrospectively compared TGK on immunotherapy and TGK on last treatment in patients with R/M HNSCC treated with PD-1/PD-L1 inhibitors in four French centers. The TGK ratio (TGKR, ratio of the slope of tumor growth before treatment and the slope of tumor growth on treatment) was calculated. Hyperprogression was defined as a TGKR ≥ 2.

Results

From September 2012 to September 2015, 34 patients were identified. Patterns of recurrence included exclusive loco-regional recurrence in 14 patients, exclusive distant metastases in 11 patients, and both in 9 patients. No pseudo-progression was observed. Hyperprogression was observed in 10 patients (29%), including 9 patients with at least a locoregional recurrence, and only 1 patient with exclusively distant metastases. Hyperprogression significantly correlated with a regional recurrence (TGKR ≥ 2: 90% versus TGKR < 2: 37%, P = 0.008), but not with local or distant recurrence. Hyperprogression was associated with a shorter progression-free survival (PFS) according to RECIST (P = 0.003) and irRECIST (P = 0.02), but not with overall survival (P = 0.77).

Conclusions

Hyperprogression was observed in 29% of patients with R/M HNSCC treated with anti-PD-L1/PD-1 agents and correlated with a shorter PFS. It occurred in 39% of patients with at least a locoregional recurrence and 9% of patients with exclusively distant metastases. No pseudo-progressions were reported. Mechanisms and causality of hyperprogression should further be assessed through prospective controlled studies.

Long-term response in patient with recurrent oropharyngeal carcinoma treated with cetuximab, docetaxel and cisplatin (TPEx) as first-line treatment followed by cetuximab maintenance

BACKGROUND

Cetuximab, an anti-EGFR monoclonal antibody in combination with platinum and 5FU is the standard of care in first-line treatment of patients with recurrent head and neck squamous cell carcinoma (HNSCC), with an expected median outcome of 10months. For this population, development of efficacious and safer therapies is still needed.

CASE REPORT

A 62-year-old male with a first recurrence of human papillomavirus positive stage IVA (T3N2bM0) adenocarcinoma of the glossotonsillar sulcus not amenable to locoregional curative treatment was offered chemotherapy as part of the TPEx clinical trial. He was treated by cetuximab (loading dose 400mg/m² on day 1 cycle 1, then 250mg/m² weekly), and chemotherapy (cisplatin 75mg/m² and docetaxel 75mg/m², on day 1). Cycles were repeated every 21days for 4 cycles (TPEx regimen) with systematic granulocyte colony-stimulating factor support at each cycle. Bi-monthly maintenance cetuximab 500mg/m² was then administered. The patient showed a clinical complete response according to RECIST 1.1 criteria after 5months maintenance, with progression-free survival of 25months. Relapses that followed were treated with stereotactic irradiation, radiofrequency ablation, cetuximab and paclitaxel. The patient is alive eleven years after cancer diagnosis and remains controlled for his disease, with a cumulative period of 59months of cetuximab administration (equivalence of 121 injections).

CONCLUSION

This case report demonstrated that TPEx regimen, by synergistic interaction between taxanes and cetuximab, followed by bimonthly cetuximab maintenance may lead to patient complete remission within the first year of treatment. Furthermore, prolonged intermittent treatment with cetuximab seems to participate in the improved survival associated with preserved quality of life. Key favorable prognostic factors may be moderate tumor differentiation, oropharyngeal location, HPV p16 positive tumor status.